Prognostic significance of MCM2high/Ki-67high in ameloblastoma

IF 0.4 Q4 DENTISTRY, ORAL SURGERY & MEDICINE
Michiyo Ando , Satoru Miyabe , Satoshi Okubo , Atsushi Nakayama , Mai Tomimatsu , Hiroshi Kawaguchi , Yuya Mizuno , Souma Okada , Masafumi Watanabe , Eri Hayakawa , Sanako Nakaya , Yasuto Sano , Reika Hasegawa , Hiroaki Nakao , Fumitaka Terasawa , Satoshi Watanabe , Shogo Hasegawa , Hitoshi Miyachi , Toru Nagao , Yoshihiko Sugita , Mitsuo Goto
{"title":"Prognostic significance of MCM2high/Ki-67high in ameloblastoma","authors":"Michiyo Ando ,&nbsp;Satoru Miyabe ,&nbsp;Satoshi Okubo ,&nbsp;Atsushi Nakayama ,&nbsp;Mai Tomimatsu ,&nbsp;Hiroshi Kawaguchi ,&nbsp;Yuya Mizuno ,&nbsp;Souma Okada ,&nbsp;Masafumi Watanabe ,&nbsp;Eri Hayakawa ,&nbsp;Sanako Nakaya ,&nbsp;Yasuto Sano ,&nbsp;Reika Hasegawa ,&nbsp;Hiroaki Nakao ,&nbsp;Fumitaka Terasawa ,&nbsp;Satoshi Watanabe ,&nbsp;Shogo Hasegawa ,&nbsp;Hitoshi Miyachi ,&nbsp;Toru Nagao ,&nbsp;Yoshihiko Sugita ,&nbsp;Mitsuo Goto","doi":"10.1016/j.ajoms.2023.10.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><span>Minichromosome maintenance (MCM) protein 2 is critical for the beginning of DNA replication and is a notable marker for proliferating cells<span>. The prognosis and management of ameloblastoma are based on histology and other factors. However, immunohistologic markers capable of detecting recurrence-prone ameloblastoma with a poor prognosis have not been adequately investigated. This study aimed to identify the association between MCM2 overexpression and recurrence prognosis and </span></span>risk stratification.</p></div><div><h3>Methods</h3><p>Thirty-two patients who had been diagnosed with ameloblastoma at our department between January 1982 and December 2019 were included in this study. Thirty-two (fifteen follicular, ten plexiform, five unicystic, two desmoplastic) subtype cases were analyzed for immunohistochemical expressions of MCM2 and Ki-67.</p></div><div><h3>Results</h3><p>Disease-free survival (DFS) analysis revealed that patients with MCM2<sup>high</sup>/Ki-67<sup>high</sup><span> ameloblastoma had a significantly shorter median survival time (63 vs. 360 months) and lower DFS survival rate (50.0% vs. 90.0%) than those with MCM2</span><sup>low</sup>/Ki-67<sup>low</sup> (<em>p</em><span> = 0.003). Multivariate analysis revealed that a location (maxillary primary ameloblastoma) and MCM2</span><sup>high</sup>/Ki-67<sup>high</sup> were independent risk factors for DFS.</p></div><div><h3>Conclusion</h3><p>Our results identified MCM2<sup>high</sup>/Ki-67<sup>high</sup> ameloblastoma as a subgroup with poor recurrent prognosis and DFS. Ameloblastoma should be assessed using immunohistochemical staining. Our study revealed that tumors with a worse recurrent prognosis require appropriate clinical surveillance.</p></div>","PeriodicalId":45034,"journal":{"name":"Journal of Oral and Maxillofacial Surgery Medicine and Pathology","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral and Maxillofacial Surgery Medicine and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212555823002405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Minichromosome maintenance (MCM) protein 2 is critical for the beginning of DNA replication and is a notable marker for proliferating cells. The prognosis and management of ameloblastoma are based on histology and other factors. However, immunohistologic markers capable of detecting recurrence-prone ameloblastoma with a poor prognosis have not been adequately investigated. This study aimed to identify the association between MCM2 overexpression and recurrence prognosis and risk stratification.

Methods

Thirty-two patients who had been diagnosed with ameloblastoma at our department between January 1982 and December 2019 were included in this study. Thirty-two (fifteen follicular, ten plexiform, five unicystic, two desmoplastic) subtype cases were analyzed for immunohistochemical expressions of MCM2 and Ki-67.

Results

Disease-free survival (DFS) analysis revealed that patients with MCM2high/Ki-67high ameloblastoma had a significantly shorter median survival time (63 vs. 360 months) and lower DFS survival rate (50.0% vs. 90.0%) than those with MCM2low/Ki-67low (p = 0.003). Multivariate analysis revealed that a location (maxillary primary ameloblastoma) and MCM2high/Ki-67high were independent risk factors for DFS.

Conclusion

Our results identified MCM2high/Ki-67high ameloblastoma as a subgroup with poor recurrent prognosis and DFS. Ameloblastoma should be assessed using immunohistochemical staining. Our study revealed that tumors with a worse recurrent prognosis require appropriate clinical surveillance.

骨髓母细胞瘤中 MCM2 高/Ki-67 高的预后意义
目的小染色体维护(MCM)蛋白 2 对于 DNA 复制的开始至关重要,是增殖细胞的一个显著标志。骨髓母细胞瘤的预后和治疗基于组织学和其他因素。然而,能够检测预后不良的易复发牙釉质母细胞瘤的免疫组织学标志物尚未得到充分研究。本研究旨在确定MCM2过表达与复发预后和风险分层之间的关联。方法本研究纳入了32例1982年1月至2019年12月期间在我科确诊为釉母细胞瘤的患者。对32例(滤泡型15例、丛状型10例、单囊型5例、去胚胎型2例)亚型病例进行了MCM2和Ki-67的免疫组化表达分析。结果无病生存期(DFS)分析显示,MCM2高/Ki-67高的骨髓母细胞瘤患者的中位生存期(63个月对360个月)和DFS生存率(50.0%对90.0%)明显短于MCM2低/Ki-67低的患者(P = 0.003)。多变量分析显示,位置(上颌骨原发性母细胞瘤)和 MCM2 高/Ki-67 高是 DFS 的独立危险因素。应使用免疫组化染色法评估牙釉质母细胞瘤。我们的研究表明,复发预后较差的肿瘤需要适当的临床监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
129
审稿时长
83 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信